Anti-KCNQ3/ BFNC2/ EBN2 monoclonal antibody
Anti-KCNQ3/ BFNC2/ EBN2 antibody for FACS & in-vivo assay
Go to KCNQ3/KCNQ3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T54132-Ab-1/ GM-Tg-hg-T54132-Ab-2 | Anti-Human KCNQ3 monoclonal antibody | Human |
GM-Tg-rg-T54132-Ab-1/ GM-Tg-rg-T54132-Ab-2 | Anti-Rat KCNQ3 monoclonal antibody | Rat |
GM-Tg-mg-T54132-Ab-1/ GM-Tg-mg-T54132-Ab-2 | Anti-Mouse KCNQ3 monoclonal antibody | Mouse |
GM-Tg-cynog-T54132-Ab-1/ GM-Tg-cynog-T54132-Ab-2 | Anti-Cynomolgus/ Rhesus macaque KCNQ3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T54132-Ab-1/ GM-Tg-felg-T54132-Ab-2 | Anti-Feline KCNQ3 monoclonal antibody | Feline |
GM-Tg-cang-T54132-Ab-1/ GM-Tg-cang-T54132-Ab-2 | Anti-Canine KCNQ3 monoclonal antibody | Canine |
GM-Tg-bovg-T54132-Ab-1/ GM-Tg-bovg-T54132-Ab-2 | Anti-Bovine KCNQ3 monoclonal antibody | Bovine |
GM-Tg-equg-T54132-Ab-1/ GM-Tg-equg-T54132-Ab-2 | Anti-Equine KCNQ3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T54132-Ab-1/ GM-Tg-hg-T54132-Ab-2; GM-Tg-rg-T54132-Ab-1/ GM-Tg-rg-T54132-Ab-2; GM-Tg-mg-T54132-Ab-1/ GM-Tg-mg-T54132-Ab-2; GM-Tg-cynog-T54132-Ab-1/ GM-Tg-cynog-T54132-Ab-2; GM-Tg-felg-T54132-Ab-1/ GM-Tg-felg-T54132-Ab-2; GM-Tg-cang-T54132-Ab-1/ GM-Tg-cang-T54132-Ab-2; GM-Tg-bovg-T54132-Ab-1/ GM-Tg-bovg-T54132-Ab-2; GM-Tg-equg-T54132-Ab-1/ GM-Tg-equg-T54132-Ab-2 |
Products Name | Anti-KCNQ3 monoclonal antibody |
Format | mab |
Target Name | KCNQ3 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-KCNQ3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species KCNQ3/ BFNC2/ EBN2 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T54132 |
Target Name | KCNQ3 |
Gene ID | 3786,110862,29682,700785,475103,101093496,281884,100057886 |
Gene Symbol and Synonyms | BFNC2,EBN2,KCNQ3,KV7.3 |
Uniprot Accession | O43525,O88944,P58126 |
Uniprot Entry Name | KCNQ3_HUMAN,KCNQ3_RAT,KCNQ3_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000184156 |
Target Classification | Ion Channel |
The target: KCNQ3, gene name: KCNQ3, also named as BFNC2, EBN2, KV7.3. This gene encodes a protein that functions in the regulation of neuronal excitability. The encoded protein forms an M-channel by associating with the products of the related KCNQ2 or KCNQ5 genes, which both encode integral membrane proteins. M-channel currents are inhibited by M1 muscarinic acetylcholine receptors and are activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2). Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.